Literature DB >> 16854358

[Classification, etiology, diagnosis and treatment of prostatitis. Other types of prostatitis. Acute and chronic prostatitis].

Juan Fernando Jiménez-Cruz1, Enrique Broseta-Rico.   

Abstract

Prostatitis is a highly prevalent nosologic entity and hence has an enormous financial impact on health systems as well as negative repercussions on patients' quality of life. The symptoms are ambiguous, diagnostic methods are controversial and treatments are long and produce inconsistent results; consequently, although not life-threatening, prostatitis has become one of those diseases that is difficult both for the patient and for the physician who attempts to help, sometimes without success. Although an infectious etiology is accepted in most cases, there are major controversies about both the diagnostic methods used and their interpretation. Recently the National Institutes of Health in the USA has proposed a new classification of this disease to substitute that used for the last twenty years. This new classification may provide a more effective approach to the diagnosis and treatment of this insidious disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16854358     DOI: 10.1157/13091448

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  2 in total

1.  Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates.

Authors:  Runsheng Li; Yan Guo; Bang Ming Han; Xiaowei Yan; Angelita G Utleg; Wei Li; Lan Chun Tu; Jian Wang; Leroy Hood; Shujie Xia; Biaoyang Lin
Journal:  Proteomics Clin Appl       Date:  2008-04-01       Impact factor: 3.494

2.  [Prevalence among males from the general population of agents responsible of not ulcerative genital tract infections, assisted in specialized care].

Authors:  C Foronda-García-Hidalgo; C Liébana-Martos; B Gutiérrez-Soto; M Expósito-Ruiz; J M Navarro-Marí; J Gutiérrez-Fernández
Journal:  Rev Esp Quimioter       Date:  2019-10-22       Impact factor: 1.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.